| Title: | Communication: Antimicrobial Activity of SMAP28 with a Targeting Domain for Porphyromonas gingivalis |
| Author(s): | Bratt CL; Kohlgraf KG; Yohnke K; Kummet C; Dawson DV; Brogden KA; |
| Address: | "Dows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA" |
| Journal Title: | Probiotics Antimicrob Proteins |
| DOI: | 10.1007/s12602-009-9028-5 |
| ISSN/ISBN: | 1867-1306 (Print) 1867-1314 (Electronic) 1867-1306 (Linking) |
| Abstract: | "Antibiotic therapy is often used with mechanical therapy to treat periodontal disease. However, complications associated with antibiotic use can occur. A 'bacteria-specific' targeted approach would eliminate some of these complications and kill specific periodontopathogens without harming the commensal bacteria. One such approach is to couple antimicrobial peptides to a ligand, pheromone, or antibody specific for the periodontopathogen, Porphyromonas gingivalis. To assess the feasibility of this approach, we attached PQGPPQ, a peptide from proline-rich protein 1 to either the N-terminus of SMAP28 (peptide ZS37-37) or the C-terminus of SMAP28 (peptide ZS37-38) to see whether it has potential as a carrier ligand to deliver SMAP28 to the surface of P. gingivalis. For Escherichia coli and Aggregatibacter actinomycetemcomitans, the median minimal inhibitory concentration (MIC) of ZS37-37 was higher than the median of SMAP28 alone, although the median MIC of ZS37-38 was lower than that of SMAP28 alone. For P. gingivalis, there was no difference in the median MIC values. For S. aureus, the median MIC was higher for ZS37-37 and ZS37-38 compared to SMAP28 alone, particularly for ZS37-38. For Fusobacterium nucleatum, the median MIC values were equal for ZS37-37 and ZS37-38 and higher than the median MIC for SMAP28 alone. Attaching PQGPPQ to SMAP28 did not greatly increase the antimicrobial activity of ZS37-37 or ZS37-38 for P. gingivalis nor substantially decrease the antimicrobial activity of ZS37-37 or ZS37-38 for the four other microorganisms tested. This is an initial step to develop a selective antimicrobial agent that has 'targeted' antimicrobial activity without adverse reactions often associated with the use of broad-spectrum antibiotics" |
| Notes: | "PubMed-not-MEDLINEBratt, Carol L Kohlgraf, Karl G Yohnke, Katie Kummet, Colleen Dawson, Deborah V Brogden, Kim A eng R01 DE014390/DE/NIDCR NIH HHS/ R01 DE014390-01A2/DE/NIDCR NIH HHS/ T32 DE014678/DE/NIDCR NIH HHS/ 2010/05/11 Probiotics Antimicrob Proteins. 2010 Mar 1; 2(1):21-5. doi: 10.1007/s12602-009-9028-5" |
